Search

Your search keyword '"Herishanu, Yair"' showing total 13 results
Start Over Author "Herishanu, Yair" Journal american journal of hematology
13 results on '"Herishanu, Yair"'

1. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Author

Visentin, Andrea, primary, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Antic, Darko, additional, Baile, Mónica, additional, Baliakas, Panagiotis, additional, Besikli‐Dimou, Sotiria, additional, Bron, Dominique, additional, Chatzileontiadou, Sofia, additional, Cordoba, Raul, additional, Correa, Juan‐Gonzalo, additional, Cuéllar‐García, Carolina, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Delgado, Julio, additional, Dimou, Maria, additional, Donaldson, David, additional, Catherwood, Mark, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, Eichhorst, Barbara, additional, Elashwah, Salma, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Frederiksen, Henrik, additional, Fürstenau, Moritz, additional, García‐Marco, José A., additional, García‐Serra, Rocío, additional, Collado, Rosa, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Glenthøj, Andreas, additional, da Silva, Maria Gomes, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández‐Rivas, José Ángel, additional, Herold, Tobias, additional, Innocenti, Idanna, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark‐David, additional, Lista, Enrico, additional, Lopez‐Garcia, Alberto, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca R., additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Niemann, Carsten U., additional, Rodrigues, Raquel Nunes, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Qvist, Kristian, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Tadmor, Tamar, additional, Capasso, Antonella, additional, Del Poeta, Giovanni, additional, Gutwein, Odit, additional, Karlsson, Linda Katharina, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Reda, Gianluigi, additional, Saghumyan, Gevorg, additional, Shrestha, Amit, additional, Te Raa, Doreen, additional, Tonino, Sanne H., additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, van Kampen, Roel, additional, Wasik‐Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Pocali, Barbara, additional, Vandenberghe, Elisabeth, additional, Iyengar, Sunil, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Cuneo, Antonio, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2023
Full Text
View/download PDF

2. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study

Author

Levi, Shai, primary, Bronstein, Yotam, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Ziv‐Baran, Tomer, additional, Del Poeta, Giovanni, additional, Bairey, Osnat, additional, Del Principe, Maria Ilaria, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Braester, Andrei, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonio, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Perry, Chava, additional, Gattei, Valter, additional, Gentile, Massimo, additional, and Herishanu, Yair, additional

Published
2022
Full Text
View/download PDF

4. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Author

Morabito, Fortunato, primary, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Recchia, Anna Grazia, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Tripepi, Giovanni, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Cutrona, Giovanna, additional, Jaksic, Ozren, additional, Olivieri, Jacopo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

5. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Cassin, Ramona, additional, D′Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Monti, Paola, additional, Menichini, Paola, additional, Olivieri, Jacopo, additional, Cutrona, Giovanna, additional, Rossi, Davide, additional, Cuneo, Antonio, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

6. Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Botta, Cirino, additional, Caracciolo, Daniele, additional, Cassin, Ramona, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Cutrona, Giovanna, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

7. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

Author

Merkel, Drorit, Filanovsky, Kalman, Gafter-Gvili, Anat, Vidal, Liat, Aviv, Ariel, Gatt, Moshe E., Silbershatz, Itay, Herishanu, Yair, Arad, Ariela, Tadmor, Tamar, Dally, Najib, Nemets, Anatoly, Rouvio, Ory, Ronson, Aharon, Herzog-Tzarfati, Katrin, Akria, Luiza, Braester, Andrei, Hellmann, Ilana, Yeganeh, Shay, Nagler, Arnon, Leiba, Ronit, Mittelman, Moshe, and Ofran, Yishai

Published
2013
Full Text
View/download PDF

9. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

Author

Herishanu, Yair, primary, Shaulov, Adir, additional, Fineman, Riva, additional, Bašić‐Kinda, Sandra, additional, Aviv, Ariel, additional, Wasik‐Szczepanek, Ewa, additional, Jaksic, Ozren, additional, Zdrenghea, Mihnea, additional, Greenbaum, Uri, additional, Mandac, Inga, additional, Simkovic, Martin, additional, Morawska, Marta, additional, Benjamini, Ohad, additional, Spacek, Martin, additional, Nemets, Anatoly, additional, Bairey, Osnat, additional, Trentin, Livio, additional, Ruchlemer, Rosa, additional, Laurenti, Luca, additional, Stanca Ciocan, Oana, additional, Doubek, Michael, additional, Shvidel, Lev, additional, Dali, Nagib, additional, Mirás, Fátima, additional, De Meûter, Anne, additional, Dimou, Maria, additional, Mauro, Francesca R., additional, Coscia, Marta, additional, Bumbea, Horia, additional, Szász, Róbert, additional, Tadmor, Tamar, additional, Gutwein, Odit, additional, Gentile, Massimo, additional, Scarfò, Lydia, additional, Tedeschi, Alessandra, additional, Sportoletti, Paolo, additional, Gimeno Vázquez, Eva, additional, Marquet, Juan, additional, Assouline, Sarit, additional, Papaioannou, Maria, additional, Braester, Andrei, additional, Levato, Luciano, additional, Gregor, Michael, additional, Rigolin, Gian M., additional, Loscertales, Javier, additional, Medina Perez, Angeles, additional, Nijziel, Marten R., additional, Popov, Viola M., additional, Collado, Rosa, additional, Slavutsky, Irma, additional, Itchaki, Gilad, additional, Ringelstein, Shimrit, additional, Goldschmidt, Neta, additional, Perry, Chava, additional, Levi, Shai, additional, Polliack, Aaron, additional, and Ghia, Paolo, additional

Published
2020
Full Text
View/download PDF

10. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

Author

Perry, Chava, primary, Ben Barouch, Sharon, additional, Goldschmidt, Neta, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Shvidel, Lev, additional, Bairey, Osnat, additional, Lavi, Noa, additional, Horowitz, Netanel, additional, Avigdor, Avraham, additional, Lebel, Eyal, additional, Sofer, Orit, additional, Ram, Ron, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

12. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.

Author

Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, Bairey O, Del Principe MI, Fineman R, Mauro FR, Gutwein O, Reda G, Ruchlemer R, Sportoletti P, Laurenti L, Shvidel L, Coscia M, Tadmor T, Varettoni M, Aviv A, Murru R, Braester A, Chiarenza A, Visentin A, Pietrasanta D, Loseto G, Zucchetto A, Bomben R, Olivieri J, Neri A, Rossi D, Gaidano G, Trentin L, Foà R, Cuneo A, Perry C, Gattei V, Gentile M, and Herishanu Y

Subjects
Humans, Rituximab therapeutic use, Cyclophosphamide therapeutic use, Vidarabine therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Published
2023
Full Text
View/download PDF

13. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.

Author

Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, and Ofran Y

Subjects
Adult, Aged, Aged, 80 and over, Chromosome Aberrations, Disease Susceptibility, Female, Humans, Incidence, Infections epidemiology, Infections immunology, Infections physiopathology, Israel epidemiology, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute immunology, Male, Methylation drug effects, Middle Aged, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes immunology, Neutropenia etiology, Retrospective Studies, Risk Factors, Severity of Illness Index, Thrombocytopenia etiology, Antimetabolites, Antineoplastic therapeutic use, Azacitidine therapeutic use, Infections complications, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute drug therapy, Myelodysplastic Syndromes complications, Myelodysplastic Syndromes drug therapy
Abstract

Hypomethylating agents have become the standard therapy for patients with high-risk myelodysplastic syndrome (MDS). In Israel, azacitidine (AZA) is routinely used. Yet, infectious complications are common during AZA therapy. The current study was aimed to evaluate the incidence and predisposing risk factors for infections in AZA-treated patients. This retrospective study included patients treated with AZA in 18 Israeli medical institutions between 2008 and 2011. Data on 184 patients [157 high-risk MDS and 27 acute myeloid leukemia (AML)], with a median age of 71.6 (range 29-92) were recorded. Overall, 153 infectious events were reported during 928 treatment cycles (16.5%) administered to 100 patients. One hundred fourteen, 114/153 (75%) events required hospitalization and 30 (19.6%) were fatal. In a univariate analysis, unfavorable cytogenetics, low neutrophil, hemoglobin (Hb) and platelet (PLT) counts were found to be associated with infections (24.4% vs. 12.9%, P < 0.0001; 27% vs. 13.5%, P < 0.0001; 20.4% vs. 11%, P < 0.0001 and 29.2% vs. 14.2%, P < 0.0001, respectively). In multivariate analysis, only low Hb level, low PLT count, and unfavorable cytogenetics remained significant. Prior to therapy, poor cytogenetics, PLT count below 20 × 10⁹/L and neutrophil count below 0.5 × 10⁹/L were predictive of the risk of infection during the first two cycles of therapy. In conclusion, patients with unfavorable cytogenetics, presenting with low neutrophil and PLT counts, are susceptible to infections. Evaluation of infection risk should be repeated prior to each cycle. Patients with poor cytogenetics in whom AZA is prescribed despite low PLT count are particularly at high risk for infections and infection prophylaxis may be considered., (Copyright © 2012 Wiley Periodicals, Inc.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results